All posts by admin

10Apr/14

Natco seeks to block Gilead's hepatitis C drug patent in India: source – Reuters


Economic Times

Natco seeks to block Gilead’s hepatitis C drug patent in India: source
Reuters
Gilead, whose medicine has been hailed by doctors as a breakthrough in treating the liver-destroying disease, has come under fire over its product’s $1,000 per pill price tag in the United States. India’s patent laws allow a third party to dispute the
WHO joins clamour to make new hepatitis C pills affordableDaily News & Analysis
Gilead aims to license hepatitis C drug to 3-4 Indian firmsReuters India
US drug industry group defends price of Gilead hepatitis drugChicago Tribune (blog)
USTrade Voice –Businessweek
all 222 news articles »
10Apr/14

Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are … – PR Newswire (press release)

Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are
PR Newswire (press release)
It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries’ Treanda, Mundipharma’s Ribomustin/Levact, Symbio Pharmaceuticals/Eisai’s Treakisym) in combination with rituximab, …

and more »